Hematology最新文献

{"title":"In-hospital and short-term outcomes in patients with atrial fibrillation undergoing chimeric antigen receptor-T cell therapy.","authors":"Nan Zhao, Wen Li, Qian Chen, Qi Zhang, Qiuyan Yu, Na Liu, Xunxun Zhu, Zixun Yin, Hui Wang, Kui Zhang, Chi Zhou, Min Fang, Hongjing Dong","doi":"10.1080/16078454.2026.2662692","DOIUrl":"https://doi.org/10.1080/16078454.2026.2662692","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative immunotherapy for hematologic malignancies. Cardiovascular complications associated with CAR-T therapy have also received increasing attention. However, the impact of atrial fibrillation (AF) on outcomes in patients undergoing CAR-T therapy remains poorly understood.</p><p><strong>Methods: </strong>We conducted a retrospective study using the National Readmission Database (NRD) to identify adult patients who underwent CAR-T therapy between 2017 and 2020. We divided the patients into two groups based on the presence of AF to study in-hospital and 30-day outcomes. Propensity score matching was performed, and outcomes were analyzed using multivariable logistic regression and Cox proportional hazards models. The primary outcomes included in-hospital mortality, stroke, sepsis, and 30-day readmission.</p><p><strong>Results: </strong>A total of 3,003 hospitalizations were identified, incluing 162 (5.39%) patients with AF. Patients in the AF group were older and more likely to be male. Compared with patients without AF, those with AF had higher rates of in-hospital mortality (7.4% vs 3.2%; <i>P</i> = 0.007), sepsis (18.5% vs 8.8%; <i>P</i> < 0.001), and stroke (8.0% vs 3.2%; <i>P</i> < 0.001). No significant differences were observed in neurotoxicity or acute kidney injury. In 30-day readmissions, there were no differences in all-cause readmission or in readmissions due to cancer- or treatment-related events, sepsis or infection, and neurologic events.</p><p><strong>Conclusion: </strong>Among patients undergoing CAR-T cell therapy, AF was associated with a higher risk of in-hospital mortality, stroke and sepsis. However, the 30-day all-cause readmission rate showed no difference between the AF group and the non-AF group.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2662692"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OVCA2 acts as an oncogene in pediatric AML by negatively regulating CDKN1A to drive cell cycle progression.","authors":"Wanyan Jiao, Saisai Cheng, Xiao Yang, Haiyan Liu, Xiaodong Tang, Qianlong Li, Ying Li, Bi Zhou","doi":"10.1080/16078454.2026.2665020","DOIUrl":"https://doi.org/10.1080/16078454.2026.2665020","url":null,"abstract":"<p><strong>Objectives: </strong>Pediatric acute myeloid leukemia (AML) is biologically distinct from adult AML and carries a poor prognosis. OVCA2, a serine hydrolase with context-dependent roles, has unknown function in AML. We aimed to investigate its role, regulation, and clinical significance in pediatric AML.</p><p><strong>Methods: </strong>OVCA2 was identified as a downstream target of a pediatric AML-specific core transcriptional regulatory circuit using CUT&Tag integrative analysis. Expression and prognostic associations were assessed in TARGET (pediatric) and TCGA (adult) datasets. Functional validation via lentiviral shRNA knockdown was performed in MV4-11 and Kasumi-1 cells using CCK-8, colony formation, and cell cycle assays. RNA-seq and GSEA elucidated mechanisms. Co-knockdown of CDKN1A tested functional rescue.</p><p><strong>Results: </strong>OVCA2 was significantly upregulated in AML and correlated with worse overall survival exclusively in the pediatric cohort. Knockdown impaired proliferation, colony formation, and induced G1 arrest, with reduced C-MYC and CDK2 levels. Transcriptomic analysis revealed activation of 'Negative Regulation of Cell Population Proliferation' pathway, with CDKN1A as a top upregulated gene. Co-knockdown of CDKN1A partially rescued the anti-proliferative effect.</p><p><strong>Discussion: </strong>OVCA2 acts as a novel oncogene in pediatric AML by transcriptionally repressing CDKN1A to drive cell cycle progression. Its age-specific prognostic association and origin from a pediatric AML core regulatory circuit highlight its role in age-related regulatory networks.</p><p><strong>Conclusion: </strong>OVCA2 represents a promising therapeutic target in pediatric AML, with its effects mediated through CDKN1A repression.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2665020"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social determinants of health associated with multiple myeloma incidence and survival among a low-income cohort in the Southeastern U.S.","authors":"Anna Junkins, Wanqing Wen, Loren Lipworth, Xijing Han, Heather Munro, Michael T Mumma, Martha J Shrubsole, Wei Zheng, Eden Biltibo, Staci Sudenga","doi":"10.1080/16078454.2026.2653275","DOIUrl":"10.1080/16078454.2026.2653275","url":null,"abstract":"<p><strong>Objectives: </strong>Multiple myeloma (MM) is the second most common hematologic malignancy in the U.S.; however, the etiology is poorly understood. We investigated social determinants of health (SDoH) associated with MM incidence and survival among low-income Black and White participants in the Southern Community Cohort Study (SCCS).</p><p><strong>Methods: </strong>The SCCS enrolled participants aged 40-79 years from 12 Southeastern states. We examined associations between SDoH (residential racial segregation, neighborhood deprivation, population density, persistent poverty, and rurality) geocoded to zip code, with MM incidence and all-cause mortality using multivariable Cox regression analyses. Additional stratified analyses examined MM incidence by obesity status.</p><p><strong>Results: </strong>Among 74,294 participants, there were 162 MM cases, 133 self-identified as Black individuals and 29 self-identified as White individuals. Living in the highest vs. lowest deprivation areas was associated with 2-fold increased MM risk (HR:2.24; 95% CI:1.01-4.95). Among MM cases, those living in the least vs. most residentially segregated areas had 2-fold increased mortality (HR:2.21; 95% CI:1.03-4.74). Among participants who were not obese, those who lived in the most densely populated areas had a reduced risk of MM compared to those who lived in the least densely populated areas (HR:0.31; 95% CI: 0.14-0.67); and those who lived in urban vs. rural areas had a reduced risk (HR:0.52; 95% CI: 0.32-0.85).</p><p><strong>Discussion: </strong>SDoH factors including neighborhood deprivation and residential racial segregation could influence MM risk and survival among low-income populations.</p><p><strong>Conclusion: </strong>SDoH factors should be considered when developing strategies to reduce overall MM burden, and disparities among people with lower socioeconomic backgrounds.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2653275"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.","authors":"Sihui Chen, Zhenqi Lou, Jieyang Zhu, Jun Xue, Biao Huang, Zinan Lin, Yun Li, Hongjuan Yang","doi":"10.1080/16078454.2026.2662818","DOIUrl":"https://doi.org/10.1080/16078454.2026.2662818","url":null,"abstract":"<p><strong>Objectives: </strong>Lactylation and liquid-liquid phase separation related genes have been reported to be associated with tumor prognosis and immunity, but their specific influence on the prognosis and immune characteristics of diffuse large B-cell lymphoma (DLBCL) remains unclear.</p><p><strong>Methods: </strong>GSE56315 (33 control samples and 55 DLBCL patient samples) has been used to screen for lactylation and liquid‒liquid phase separation related differentially expressed genes (LLRDEGs). Based on the optimal cutoff, LLRDEGs associated with DLBCL prognosis (overall survival) was further screened through LASSO and univariate Cox regression. Then, based on the GSE10846 dataset (414 DLBCL samples), a prognostic model was constructed based on the LLRDEGs. The Kaplan-Meier curve is used to evaluate the prognostic value (median risk score). And validate the prognostic model on an independent external validation dataset (GSE181063 (1310 DLBCL samples)). Finally, further analysis was conducted on consensus clustering, biological pathways, the immune microenvironment and drug sensitivity.</p><p><strong>Results: </strong>4 LLRDEGs were ultimately identified as genes associated with the DLBCL' prognosis. A prognostic model was constructed based on the 4 LLRDEGs. An independent external validation dataset confirmed the prognostic model's prognostic value. 4 LLRDEGs were significantly correlated with various immune cells.</p><p><strong>Discussion: </strong>This study screened four LLRDEGs significantly associated with prognosis and constructed a prognostic risk stratification model. The Kaplan-Meier curve confirms the prognostic value of the prognostic risk stratification model. This prognostic model is related to the clinical characteristics and immune microenvironment of DLBCL patients.</p><p><strong>Conclusion: </strong>This study elucidates the role of LLRDEGs in the prognosis and immune features of DLBCL, providing insights into potential therapeutic targets.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2662818"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.","authors":"Baozhi Fang, Xiao Yu, Yifei Zhou, Qiudan Shen, Muzhi Yuan, Peng Wang, Mingen Lü, Guangsheng He","doi":"10.1080/16078454.2026.2647316","DOIUrl":"https://doi.org/10.1080/16078454.2026.2647316","url":null,"abstract":"<p><strong>Objectives: </strong>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition characterized by intravascular hemolysis (IVH), thrombosis, and organ damage. Although C5 complement inhibitors such as eculizumab have significantly improved the prognosis of patients with PNH, persistent anemia remains in some patients.</p><p><strong>Methods: </strong>We report a patient with PNH who initially responded to eculizumab but experienced recurrent hemoglobin decrease and became transfusion-dependent after 24 weeks of treatment. Here, we present the clinical features of this patient. In addition, we reviewed the current literature to characterize persistent anemia caused by non-dominant residual IVH following C5 inhibitor therapy in PNH, along with related biomarker assessment and clinical applications of proximal complement inhibitors.</p><p><strong>Results: </strong>Lactate dehydrogenase (LDH) levels did not significantly increase, and the direct antiglobulin test (DAT) with anti-C3d was only weakly positive (titre 1:16). The changes in free hemoglobin, haptoglobin, and type III red blood cells (RBC) (total loss of CD59) indicated subclinical yet active IVH. After the introduction of iptacopan monotherapy for six weeks, the levels of LDH, free hemoglobin, and haptoglobin normalized, and the need for further transfusions was eliminated. The proportion of type III RBC increased to 57.3%.</p><p><strong>Conclusion: </strong>This case suggests that persistent anemia in patients with PNH following C5 inhibitor therapy might be associated with subclinically active IVH, and proximal complement inhibitors, such as iptacopan, may offer effective management of this condition.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2647316"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.","authors":"Liling Lu, Shenglan Lin, Yating Chen, Yiqun Huang","doi":"10.1080/16078454.2026.2653404","DOIUrl":"https://doi.org/10.1080/16078454.2026.2653404","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate temporal trends in second primary malignancy (SPM) risk among long-term multiple myeloma (MM) survivors across treatment eras.</p><p><strong>Methods: </strong>This retrospective cohort study utilized the SEER 17 registries database (1975-2022). Patients with MM as first primary malignancy surviving ≥5 years were stratified into four treatment eras: Era 1 (≤2000, pre-novel agents), Era 2 (2001-2010, proteasome inhibitor/IMiD introduction), Era 3 (2011-2015, new-generation IMiDs), and Era 4 (2016+, daratumumab era). SPM was defined as any malignancy occurring ≥5 years post-diagnosis. Cumulative incidence was estimated using competing risk analysis.</p><p><strong>Results: </strong>Among 52,497 MM patients, 15,402 (29.34%) achieved 5-year survival. Overall, 1,408 patients (9.14%) developed SPM over 72,951.70 person-years. SPM rates declined significantly across eras: 11.43% (Era 1), 10.45% (Era 2), 7.78% (Era 3), and 2.45% (Era 4) (P<i>trend</i> < 0.001). The most common SPMs were prostate (13.81%), lung (10.17%), and breast cancer (7.42%). Acute myeloid leukemia (6.78%) remained notable among hematologic malignancies. Sensitivity analysis among 10-year survivors confirmed the declining trend.</p><p><strong>Conclusions: </strong>SPM rates progressively declined from Era 1 through Era 3, with encouraging early signals in Era 4 requiring longer follow-up. The shift from alkylating agents to targeted therapies may contribute to reduced SPM occurrence, providing preliminary evidence for improved long-term safety of contemporary MM treatments.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2653404"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between household pesticide exposure and anemia is modified by dietary selenium intake: a population-based study.","authors":"Jinhui Gan, Qing Xie, Xiaoqin Xin","doi":"10.1080/16078454.2026.2659975","DOIUrl":"https://doi.org/10.1080/16078454.2026.2659975","url":null,"abstract":"<p><strong>Background: </strong>While the detrimental health effects of occupational pesticide exposure are well-documented, the association between household pesticide use and anemia in the general adult population remains underexplored. Furthermore, the potential for dietary factors, such as selenium, to modulate this relationship is unknown.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis using data from 14,708 adults (≥18 years) who participated in the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2018. Household pesticide exposure was self-reported. Anemia was defined according to World Health Organization criteria (hemoglobin <13 g/dL for men, <12 g/dL for women). Dietary selenium intake was categorized as low (<125 µg/day) or high (≥125 µg/day). Multivariable logistic regression models were used to evaluate the association between pesticide exposure and anemia. The modifying effect of selenium was assessed using an interaction term and stratified analyses.</p><p><strong>Results: </strong>Of the 14,447 participants included in the final analysis, 1,516 (10.5%) reported household pesticide exposure, and 1,506 (10.4%) met the criteria for anemia. Household pesticide exposure was associated with higher odds of anemia (OR = 1.23; 95% CI: 1.03-1.47). A significant interaction with selenium intake was observed (<i>p</i> = 0.032). Among participants with low selenium intake, pesticide exposure increased anemia risk (OR = 1.31; 95% CI: 1.06-1.61), whereas no association was found in the high selenium group (OR = 0.74; 95% CI: 0.49-1.11).</p><p><strong>Conclusion: </strong>This study provides novel evidence that household pesticide exposure is associated with a modestly increased prevalence of anemia in the general U.S. adult population. Furthermore, our findings suggest that adequate dietary selenium intake may mitigate this hematological risk.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2659975"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First report of a rare hemoglobin variant in the Chinese population: clinical and hematological characteristics of Hb Norton [HBA2:c.217C>G] and its impact on HbA1c testing: a case report.","authors":"Jian Shang, Zirui Cao, Weidong Chen, Huijun Yang","doi":"10.1080/16078454.2026.2665490","DOIUrl":"https://doi.org/10.1080/16078454.2026.2665490","url":null,"abstract":"<p><strong>Objectives: </strong>Hemoglobin (Hb) variants are a common type of single-gene disorder and a frequent source of interference in HbA_1c testing. Here, we first report a rare Hb variant, Hb Norton [HBA2:c.217C>G], in the Chinese population.</p><p><strong>Methods and results: </strong>A 38-year-old man presented with a normal clinical and hematological phenotype. He was suspected of carrying an Hb variant following an HbA_1c measurement using a high-performance liquid chromatography (HPLC) method (Bio-Rad D100), which resulted in an extremely high value of 20.24%. HbA_1c was reanalyzed using a capillary electrophoresis (CE) method (Capillarys3 TERA) and a boronate affinity HPLC system (Premier Hb9210), and the results were 5.49% and 5.60%, respectively. Hemoglobin analysis by CE and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) revealed a variant peak with a mass-to-charge ratio (m/z) = 10105 Da. Sanger sequencing confirmed the presence of a rare Hb variant, Hb Norton [HBA2:c.217C>G]. It was conclusively confirmed that the co-elution of Hb Norton and HbA_1c components led to the falsely elevated HbA_1c values.</p><p><strong>Conclusions: </strong>Some rare variants can severely affect HbA_1c analysis. When encountering abnormally high values that are difficult to explain, one should consider whether variant interference is present.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2665490"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life among older adults undergoing hematopoietic stem cell transplantation: a narrative review.","authors":"Xiao-Lin Liu, Xin-Xin He, Mei-Jiao Li, Mei Guo, Dan Li, Xiao-Dong Xu","doi":"10.1080/16078454.2026.2659974","DOIUrl":"https://doi.org/10.1080/16078454.2026.2659974","url":null,"abstract":"<p><strong>Introduction: </strong>With the global aging population and the expanded application of hematopoietic stem cell transplantation (HSCT) in older adults, understanding quality of life (QOL) outcomes in this vulnerable group is of paramount importance.</p><p><strong>Objectives: </strong>This narrative review synthesizes current evidence to (1) describe the trajectory of QOL in older HSCT recipients; (2) identify the key transplant-related, physiological, and psychosocial determinants of post-transplant well-being; and (3) evaluate existing and emerging strategies to improve patient outcomes.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed/MEDLINE, Web of Science, and Embase (inception to December 2024) using terms related to HSCT, older adults, and QOL. Articles focusing on patients aged ≥60 years were selected to synthesize evidence on QOL outcomes, influencing factors, and interventions.</p><p><strong>Results: </strong>Older adults experience significant QOL decline, typically nadiring within three months post-transplant, with infrequent full recovery to baseline. Key determinants include transplant modality (allogeneic vs. autologous), regimen intensity, and complications like graft-versus-host disease. These interact with patient-specific factors such as frailty, nutritional status, psychological distress, and social support. Emerging multidisciplinary strategies, including optimized conditioning regimens, structured psychosocial support, and geriatric assessment-informed enhanced recovery programs, show promise in mitigating QOL impairment.</p><p><strong>Discussion: </strong>The evidence highlights the multifactorial nature of QOL in this population. A critical gap remains the lack of standardized, HSCT-specific geriatric assessment tools to guide personalized interventions. While multidisciplinary care is advocated, its components require further refinement and validation for older adults.</p><p><strong>Conclusion: </strong>A holistic, patient-centered approach integrating geriatric principles is essential to improve long-term survivorship and QOL in the growing population of older adults undergoing HSCT.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2659974"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The correlation between cardiac T2*MRI and B-Type natriuretic peptides in patients with transfusion-dependent anemias and systemic iron overload: a systematic review and meta-analysis.","authors":"Mohamad Amin Kharaghani, Reza Samiee, Amirhossein Shahsavand, Shayan Forghani, Mahta Moradi, Tahereh Jangjoo Pirbazari, Elham Shahgholi","doi":"10.1080/16078454.2026.2644716","DOIUrl":"https://doi.org/10.1080/16078454.2026.2644716","url":null,"abstract":"<p><strong>Objectives: </strong>Systemic iron overload in transfusion-dependent anemias leads to progressive myocardial iron accumulation, a major cause of morbidity and mortality. This study evaluated the relationship between cardiac T2* magnetic resonance imaging (MRI) values and natriuretic peptide levels in patients with systemic iron overload.</p><p><strong>Methods: </strong>Cardiac T2* MRI magnetic resonance imaging (MRI) is the gold standard for assessing myocardial iron, but it is costly and not widely available. B-type natriuretic peptides (BNP and NT-proBNP), which reflect myocardial stress, may offer a practical biomarker alternative. This systematic review and meta-analysis evaluated the relationship between cardiac T2* MRI values and natriuretic peptide levels in patients with systemic iron overload. Nine studies involving 783 patients were included in the systematic review, and pooled analyses were performed using data from seven studies.</p><p><strong>Results: </strong>Pooled data from seven studies showed a moderate inverse correlation between T2* values and natriuretic peptide levels (r = -0.30, 95% CI -0.51 to -0.06), indicating higher peptide levels with greater myocardial iron deposition. Patients with cardiac iron overload (T2* < 20 ms) had significantly higher peptide levels (standardized mean difference = -0.71, 95% CI -1.32 to -0.11), with pooled mean concentrations of 321.1 (95% CI 248.3-393.9) compared with 179.0 (95% CI 134.3-223.6) in those without cardiac iron overload (T2* > 20 ms).</p><p><strong>Discussion: </strong>These findings suggest that natriuretic peptide levels reflect myocardial stress associated with cardiac iron burden and may provide clinically relevant information on myocardial iron overload.</p><p><strong>Conclusion: </strong>Although natriuretic peptides cannot replace cardiac MRI, they may serve as accessible, low-cost adjunct biomarkers for screening, monitoring, and early warning of myocardial iron overload, particularly where MRI is limited. Further prospective studies are warranted to validate their role in longitudinal assessment and risk prediction.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2644716"},"PeriodicalIF":1.6,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}